A multi-centre, double-blind, randomised, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Birch Modified Allergen Tyrosine adsorbed + MPL in the prevention of seasonal symptoms in subjects with allergic rhinoconjunctivitis due to birch pollen
Latest Information Update: 17 Sep 2018
At a glance
- Drugs Grass pollen allergy immunotherapy (Primary) ; Monophosphoryl lipid A
- Indications Allergic rhinoconjunctivitis
- Focus Therapeutic Use
- Sponsors Allergy Therapeutics
- 15 Sep 2018 Status changed from active, no longer recruiting to completed.
- 05 Sep 2018 This trial has been completed in Poland (End date: 20 Jun 2018).
- 26 Jul 2018 This trial has been completed in Germany (End date: 20 Jun 2018).